Brokerages Expect Oxford Immunotec Global PLC (NASDAQ:OXFD) Will Announce Earnings of -$0.05 Per Share

Equities research analysts expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will report ($0.05) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Oxford Immunotec Global’s earnings, with estimates ranging from ($0.09) to $0.00. Oxford Immunotec Global reported earnings of ($0.24) per share in the same quarter last year, which indicates a positive year over year growth rate of 79.2%. The business is expected to report its next earnings report on Friday, November 8th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full year earnings of ($0.17) per share for the current financial year, with EPS estimates ranging from ($0.19) to ($0.13). For the next year, analysts forecast that the business will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.20) to ($0.12). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.07. The business had revenue of $19.60 million during the quarter, compared to the consensus estimate of $19.32 million. Oxford Immunotec Global had a return on equity of 14.76% and a net margin of 208.48%. The company’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.25) EPS.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Friday, October 4th. ValuEngine raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, September 25th. Cowen set a $20.00 target price on Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, TheStreet downgraded Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Shares of OXFD stock traded up $0.15 during trading hours on Thursday, reaching $15.35. 6,514 shares of the company’s stock were exchanged, compared to its average volume of 235,432. The company has a market cap of $418.83 million, a P/E ratio of 30.27 and a beta of 0.43. The company’s 50 day moving average is $14.46 and its two-hundred day moving average is $14.70. Oxford Immunotec Global has a 1 year low of $11.88 and a 1 year high of $18.60. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.35 and a quick ratio of 12.76.

In related news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $19.90, for a total value of $59,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Wrighton-Smith sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $14.92, for a total value of $298,400.00. Following the completion of the transaction, the chief executive officer now directly owns 404,538 shares of the company’s stock, valued at $6,035,706.96. The disclosure for this sale can be found here. Insiders sold a total of 63,000 shares of company stock valued at $983,000 over the last ninety days. 4.21% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at approximately $108,000. River & Mercantile Asset Management LLP purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at approximately $1,980,000. Susquehanna International Group LLP purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at approximately $162,000. Zacks Investment Management purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at approximately $345,000. Finally, Jane Street Group LLC purchased a new position in Oxford Immunotec Global during the second quarter worth $557,000. 94.09% of the stock is owned by hedge funds and other institutional investors.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Recommended Story: How prevalent are 12b-1 fees?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.